EU Commission approves first RSV vaccine for infants

The European Commission has given the green light to Pfizer's Abrysvo, the first vaccine to protect the elderly as well as infants up to six months old against respiratory infections caused by RSV.

"As the autumn and winter seasons approach, this vaccine can help prevent serious RSV consequences in some of our most vulnerable citizens. This is particularly important for children, for whom RSV is a leading cause of hospitalisation in the EU," said EU Health commissioner Stella Kyriakides. She recommends that member states include the vaccine in national immunisation campaigns.

RSV, or respiratory syncytial virus, is a common respiratory infection in infants. The virus usually causes mild symptoms such as a runny nose or dry cough. Most people recover quickly, but in infants, the elderly, or people with lung or heart disease or diabetes, RSV infection can be serious and lead to pneumonia.

"As the autumn and winter approach, this vaccine can help prevent serious RSV consequences in some of our most vulnerable citizens"

Abrysvo, a vaccine developed by pharmaceutical giant Pfizer, can protect infants from infection by vaccinating pregnant women. Earlier this week, US authorities also approved the vaccine. In June, the Commission already gave the green light to different RSV vaccine produced by British pharmaceutical company GSK, but this one is aimed at protecting older people, not babies.



Related news:

Website preview
EMA approves first RSV vaccine, to be produced in Wallonia
The European Medicines Agency EMA has approved the RSV vaccine Arexvy from British pharmaceutical company GSK. This is the first-ever vaccine against this common respiratory infection and will in part be produced at the company's vaccine plant in Wavre, Wallonia.
Website preview
Pharma company GSK invests 70 million euros in RSV vaccine production
British pharmaceutical company GlaxoSmithKline (GSK) is going to invest 70 million euros in its vaccine factory in the Belgian city of Wavre. The funds will go towards the production of the antigen for vaccines against RSV, the respiratory infection that especially affects very young children and older adults.

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.


Belga News Agency delivers dependable, rapid and high-quality information 24 hours a day, 7 days a week, from Belgium and abroad to all Belgian media. The information covers all sectors, from politics, economics and finance to social affairs, sports and culture, not to mention entertainment and lifestyle.

Every day, our journalists and press photographers produce hundreds of photos and news stories, dozens of online information items, plus audio and video bulletins, all in both national languages. Since the end of March 2022 English has been added as a language.

For public institutions, businesses and various organisations that need reliable information, Belga News Agency also offers a comprehensive range of corporate services to meet all their communication needs.


Arduinkaai 29 1000 Brussels